JP5568008B2 - ペプチドチロシナーゼインヒビターおよびその使用 - Google Patents

ペプチドチロシナーゼインヒビターおよびその使用 Download PDF

Info

Publication number
JP5568008B2
JP5568008B2 JP2010515078A JP2010515078A JP5568008B2 JP 5568008 B2 JP5568008 B2 JP 5568008B2 JP 2010515078 A JP2010515078 A JP 2010515078A JP 2010515078 A JP2010515078 A JP 2010515078A JP 5568008 B2 JP5568008 B2 JP 5568008B2
Authority
JP
Japan
Prior art keywords
peptide
tyrosinase
skin
radsradc
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010515078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010531892A (ja
JP2010531892A5 (enExample
Inventor
エム ハンタッシュ バジル
Original Assignee
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー filed Critical ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー
Publication of JP2010531892A publication Critical patent/JP2010531892A/ja
Publication of JP2010531892A5 publication Critical patent/JP2010531892A5/ja
Application granted granted Critical
Publication of JP5568008B2 publication Critical patent/JP5568008B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2010515078A 2007-06-27 2008-06-25 ペプチドチロシナーゼインヒビターおよびその使用 Expired - Fee Related JP5568008B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93733107P 2007-06-27 2007-06-27
US60/937,331 2007-06-27
PCT/US2008/068186 WO2009003037A1 (en) 2007-06-27 2008-06-25 Peptide tyrosinase inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014085691A Division JP2014193163A (ja) 2007-06-27 2014-04-17 ペプチドチロシナーゼインヒビターおよびその使用

Publications (3)

Publication Number Publication Date
JP2010531892A JP2010531892A (ja) 2010-09-30
JP2010531892A5 JP2010531892A5 (enExample) 2011-08-11
JP5568008B2 true JP5568008B2 (ja) 2014-08-06

Family

ID=40186023

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010515078A Expired - Fee Related JP5568008B2 (ja) 2007-06-27 2008-06-25 ペプチドチロシナーゼインヒビターおよびその使用
JP2014085691A Pending JP2014193163A (ja) 2007-06-27 2014-04-17 ペプチドチロシナーゼインヒビターおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014085691A Pending JP2014193163A (ja) 2007-06-27 2014-04-17 ペプチドチロシナーゼインヒビターおよびその使用

Country Status (7)

Country Link
US (2) US8026208B2 (enExample)
EP (1) EP2180897B1 (enExample)
JP (2) JP5568008B2 (enExample)
KR (1) KR101507188B1 (enExample)
CN (2) CN101795703B (enExample)
CA (1) CA2728140C (enExample)
WO (1) WO2009003037A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641591B1 (en) 1999-08-26 2003-11-04 John H. Shadduck Instruments and techniques for controlled removal of epidermal layers
US8048089B2 (en) 2005-12-30 2011-11-01 Edge Systems Corporation Apparatus and methods for treating the skin
WO2014151104A1 (en) 2013-03-15 2014-09-25 Edge Systems Llc Devices, systems and methods for treating the skin
US10172644B2 (en) 2006-03-29 2019-01-08 Edge Systems Llc Devices, systems and methods for treating the skin
US9566088B2 (en) 2006-03-29 2017-02-14 Edge Systems Llc Devices, systems and methods for treating the skin
GB0612669D0 (en) * 2006-06-27 2006-08-09 Univ Leeds Biomarkers for preeclampsia
WO2009003037A1 (en) * 2007-06-27 2008-12-31 The Board Of Trustees Of The Leland Stanford Junior University Peptide tyrosinase inhibitors and uses thereof
EP2240099B1 (en) 2008-01-04 2018-02-21 Edge Systems LLC Apparatus for treating the skin
US8814836B2 (en) 2008-01-29 2014-08-26 Edge Systems Llc Devices, systems and methods for treating the skin using time-release substances
WO2009097451A1 (en) 2008-01-29 2009-08-06 Edge Systems Corporation Apparatus and method for treating the skin
US9687591B2 (en) 2010-03-31 2017-06-27 Agency For Science, Technology And Research Building stratified biomimetic tissues and organs using crosslinked ultrashort peptide hydrogel membranes
US8999916B2 (en) 2010-03-31 2015-04-07 Agency For Science, Technology And Research Crosslinked peptide hydrogels
SG184345A1 (en) 2010-03-31 2012-11-29 Agency Science Tech & Res Amphiphilic linear peptide/peptoid and hydrogel comprising the same
WO2011154640A2 (fr) * 2010-06-11 2011-12-15 Galderma Research & Development Modulateurs de trmp1, mmp2, mia ou ptgs1 dans le traitement du melasma
WO2011154639A2 (fr) * 2010-06-11 2011-12-15 Galderma Research & Development Modulateurs de edn3 et/ou ednrb dans le traitement du melasma
WO2012154959A1 (en) * 2011-05-11 2012-11-15 Elixir Institute Of Regenerative Medicine Peptide tyrosinase inhibitors and uses thereof
JP6026765B2 (ja) * 2012-04-24 2016-11-16 花王株式会社 チロシナーゼ阻害剤
WO2014116187A1 (en) * 2013-01-28 2014-07-31 Agency For Science, Technology And Research Crosslinked peptide hydrogels
US10238812B2 (en) 2013-03-15 2019-03-26 Edge Systems Llc Skin treatment systems and methods using needles
EP3795204B1 (en) 2014-12-23 2023-10-25 HydraFacial LLC Device for treating the skin using a rollerball
US10179229B2 (en) 2014-12-23 2019-01-15 Edge Systems Llc Devices and methods for treating the skin using a porous member
CN107920948A (zh) 2015-07-08 2018-04-17 边缘系统有限公司 用于促进毛发生长的装置、系统和方法
KR101895906B1 (ko) * 2016-07-07 2018-10-04 주식회사 한국화장품제조 펩타이드 리포좀을 포함하는 스틱형 화장료 조성물
WO2018013609A2 (en) 2016-07-11 2018-01-18 The Regents The University Of California Synthetic melanin nanoparticles uses thereof
EP3512867B1 (en) * 2016-09-15 2020-12-16 DSM IP Assets B.V. Novel compounds
EA202091213A1 (ru) 2017-11-14 2020-08-13 Юнилевер Н.В. Пептиды для повышения содержания меланина в меланоцитах
US11419803B2 (en) 2017-12-06 2022-08-23 Conopco, Inc. Skin darkening composition
CN109180785B (zh) * 2018-11-08 2021-08-20 中国科学院上海应用物理研究所 一种具有抑制黑色素生成和抗紫外线损伤作用的美白还原多肽及其应用
US12441890B2 (en) 2019-10-30 2025-10-14 Northwestern University Selenium-containing analogues of pheomelanin and related materials and methods of making
US11291474B2 (en) 2020-01-06 2022-04-05 Ed F. Nicolas Skin treatment tool applicator tip
WO2021163701A1 (en) * 2020-02-13 2021-08-19 Escape Therapeutics, Inc. Melanoma therapeutics
KR102506020B1 (ko) * 2020-11-27 2023-03-06 웰펩 주식회사 항산화 활성 및 티로시나제 저해활성을 갖는 펩타이드 및 이를 포함하는 조성물
USD1016615S1 (en) 2021-09-10 2024-03-05 Hydrafacial Llc Container for a skin treatment device
WO2023039524A1 (en) 2021-09-10 2023-03-16 Hydrafacial Llc Devices, systems and methods for treating the skin
USD1065551S1 (en) 2021-09-10 2025-03-04 Hydrafacial Llc Skin treatment device
USD1042807S1 (en) 2021-10-11 2024-09-17 Hydrafacial Llc Skin treatment tip
USD1116120S1 (en) 2021-10-11 2026-03-03 Hydrafacial Llc Skin treatment device
USD1112778S1 (en) 2022-03-04 2026-02-10 Hydrafacial Llc Light therapy device for skin care
US12377036B2 (en) 2022-06-21 2025-08-05 Northwestern University Melanin hair dye with thickeners
USD1084369S1 (en) 2023-02-10 2025-07-15 Hydrafacial Llc Skin treatment tip
CN117106016A (zh) * 2023-09-01 2023-11-24 海南大学 阿胶源酪氨酸酶抑制肽及其应用
CN117106015B (zh) * 2023-09-01 2024-04-26 海南大学 一种椰子源活性肽及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) * 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US3978427A (en) * 1973-06-15 1976-08-31 American Optical Corporation Erbium laser device having non-masking laser rod holders
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB2103622B (en) * 1981-06-16 1986-01-15 Genentech Inc Production of foot and mouth disease vaccine from microbially expressed antigens
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
IT1164225B (it) * 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
EP0389950A1 (en) * 1989-03-23 1990-10-03 Lion Corporation Melanocyte-stimulating hormone inhibitor and external preparation containing the same
US5773291A (en) * 1989-04-26 1998-06-30 Sloan-Kettering Institute For Cancer Research Non-melanotytic mammalian cell constitutively expressing biologically active human tyrosinase and use thereof
WO1991004019A1 (en) * 1989-09-12 1991-04-04 The Regents Of The University Of California Therapeutic peptides and proteins
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
AU1194092A (en) * 1991-02-06 1992-09-07 Georgetown University Receptor blocking peptides of fibroblast growth factor receptor
US5256766A (en) * 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
US5688768A (en) * 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
NZ254752A (en) 1992-08-21 1997-06-24 Wa Pharma Ab Dna fragments encoding melanocyte stimulating hormone receptors, their use in production of encoded polypeptides and diagnostic and therapeutic methods
US5670483A (en) * 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5455228A (en) * 1993-07-02 1995-10-03 The Research Foundation Of State University Of New York Peptidase resistant thrombin receptor peptide ligand
US5603933A (en) * 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins
US5589460A (en) * 1994-05-04 1996-12-31 Innapharma, Inc. Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent
CN1179105A (zh) * 1995-01-17 1998-04-15 小马克·奎伦 α－促黑激素拮抗剂及相关方法
US6602856B1 (en) * 1995-01-17 2003-08-05 J. Mark Quillan Antagonists of alpha-melanocyte stimulating hormone and methods based thereon
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
WO1996040033A1 (en) * 1995-06-07 1996-12-19 Clarion Pharmaceuticals Inc. Non-biological patch for hemostasis
BR9708390A (pt) * 1996-03-28 2000-01-04 Trustees O Boston University Método para identificar uma substância que altera a pigmentação nos melanócitos epidérmicos de vertebrados, substância que inibe, intensifica ou modula a fosforização da tirosinase mediada pela proteìna c-beta quinase, uso de um agente que modula ou inibe a fosforização de um resìduo de serina ou de treonina mediada pela proteìna c-beta quinase, uso em peptìdeo que especificamente interfere na fosforização de resìduos de serina/treonina mediada pela proteìna c-beta quinase, uso de uma construção de dna ou de um peptìdeo para fabricar um medicamento para diminuir a pigmentação na pela, cabelo, lã ou pelo de vertebrados e uso de uma substância que modula a fosforização da tirosinase mediada pela proteìna c-beta quinase.
US6143723A (en) * 1996-05-20 2000-11-07 Ramaiah; Abburi Pigmentory agent
KR100478928B1 (ko) * 1996-11-08 2005-08-18 세이렌가부시끼가이샤 세리신또는세리신가수분해물을유효성분으로하는비의약용항산화제,화장품,식품변색방지제,음식물,심근경색치료제,동맥경화치료제,당뇨병치료제,암치료제,또는뇌줄중치료제
US6982249B1 (en) * 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
US6368877B1 (en) * 1997-06-25 2002-04-09 Massachusetts Institute Of Technology Self-assembling peptide surfaces for cell patterning and interactions
US8039026B1 (en) * 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6323219B1 (en) * 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US6256533B1 (en) * 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US20020034772A1 (en) * 1999-06-29 2002-03-21 Orlow Seth J. Methods and compositions that affect melanogenesis
US7083781B2 (en) 1999-08-19 2006-08-01 Lavipharm S.A. Film forming polymers, methods of use, and devices and applications thereof
PL363153A1 (en) * 2000-06-16 2004-11-15 Hercules Incorporated Chemically-modified antimicrobial peptides, compositions and methods of production and use
US7449180B2 (en) * 2001-02-06 2008-11-11 John Kisiday Macroscopic scaffold containing amphiphilic peptides encapsulating cells
WO2002062969A2 (en) * 2001-02-06 2002-08-15 Massachusetts Institute Of Technology Cellular reprogramming in peptide hydrogel and uses thereof
US20020182237A1 (en) * 2001-03-22 2002-12-05 The Procter & Gamble Company Skin care compositions containing a sugar amine
WO2002087530A1 (en) * 2001-04-27 2002-11-07 The General Hospital Corporation Tyrosinase assay
US6695853B2 (en) * 2001-11-21 2004-02-24 Emed, Inc. Microdermabrasion system and method of use
US7658742B2 (en) * 2001-11-21 2010-02-09 Envy Medical, Inc. Skin treatment system and method of use
US6649150B2 (en) * 2002-04-11 2003-11-18 Em Industries Skin-lightening
US7025957B2 (en) * 2002-09-06 2006-04-11 Desert Whale Jojoba Company Composition and method to whiten skin
US7125572B2 (en) * 2004-05-14 2006-10-24 Kaoder Industry Company, Ltd. Tyrosinase inhibitor extract
SI1913157T2 (sl) 2005-06-28 2017-02-28 Genentech, Inc. EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem
JP4742365B2 (ja) * 2005-10-04 2011-08-10 独立行政法人産業技術総合研究所 チロシナーゼ阻害剤、美白剤および美白外用剤
WO2009003037A1 (en) * 2007-06-27 2008-12-31 The Board Of Trustees Of The Leland Stanford Junior University Peptide tyrosinase inhibitors and uses thereof

Also Published As

Publication number Publication date
US8026208B2 (en) 2011-09-27
WO2009003037A1 (en) 2008-12-31
US20110293709A1 (en) 2011-12-01
CN101795703B (zh) 2015-05-06
EP2180897B1 (en) 2019-05-08
JP2010531892A (ja) 2010-09-30
CN103864892A (zh) 2014-06-18
CA2728140C (en) 2019-09-03
JP2014193163A (ja) 2014-10-09
EP2180897A4 (en) 2015-08-26
CN101795703A (zh) 2010-08-04
CA2728140A1 (en) 2008-12-31
KR20100039861A (ko) 2010-04-16
US8338364B2 (en) 2012-12-25
EP2180897A1 (en) 2010-05-05
KR101507188B1 (ko) 2015-03-30
US20090099093A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
JP5587772B2 (ja) オリゴペプチドチロシナーゼインヒビターおよびその使用
CN101795703B (zh) 肽酪氨酸酶抑制剂及其应用
US9567368B2 (en) Peptide tyrosinase activators
KR20200024235A (ko) 피부, 모발, 손톱 및/또는 점막의 치료 및/또는 관리에 유용한 화합물
US8877713B2 (en) Anti-aging peptides and cosmetic and/or pharmaceutical composition containing same
JP2009114187A (ja) 皮膚色素沈着の処理方法
US9320698B2 (en) Peptide tyrosinase inhibitors and uses thereof
JP7695716B2 (ja) 化粧品および医薬品に使用するためのペプチドおよび組成物
HK1191957A1 (zh) 是蛋白trf2调节剂的新型肽和包含其的组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140418

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140620

R150 Certificate of patent or registration of utility model

Ref document number: 5568008

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees